Drug Trial Radar · NCT05936151
A Study of Retatrutide (LY3437943) on Renal Function in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes
Last checked: Nov 20, 2026Latest source record: Nov 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
146
Actual
Start
Jul 20, 2023
Primary completion
Oct 1, 2025
Study completion Oct 21, 2025
Sponsor
- Lead sponsor
- Eli Lilly and CompanyEli Lilly (LLY)
- Sponsor type
- Industry
- First posted
- Jul 7, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The main purpose of this study is to investigate the effect of retatrutide on renal function in participants with overweight or obesity and chronic kidney disease (CKD), with or without Type 2 Diabetes (T2D). The study will last around 31 weeks.
Conditions
- Overweight or Obesity
- CKD
- Type 2 Diabetes
Interventions
RetatrutideDrug
Administered Subcutaneously
PlaceboDrug
Administered Subcutaneously
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline in Measured Glomerular Filtration Rate (mGFR) Using Iohexol Clearance at Week 24Time frame: Baseline, Week 24
Locations
42 sites in 5 countries. Site status is shown where the registry gives one.
The Institute for Liver Health II dba Arizona Clinical Trials - Mesa
Chandler, Arizona
Care Access - 801 South Power Road, Mesa
Mesa, Arizona
Headlands Research - Scottsdale
Scottsdale, Arizona
Medical Advancement Centers of Arizona
Tempe, Arizona
Hope Clinical Research, Inc.
Canoga Park, California
Catalina Research Institute, LLC
Montclair, California
Peninsula Research Associates
Rolling Hills Estates, California
University of Colorado Anschutz Medical Campus
Aurora, Colorado
Teradan Clinical Trials, LLC
Brandon, Florida
Suncoast Clinical Research, Inc.
New Port Richey, Florida
Great Lakes Clinical Trials - Ravenswood
Chicago, Illinois
Indiana University Health University Hospital
Indianapolis, Indiana
Prime Health and Wellness/SKYCRNG
Fayette, Mississippi
Palm Research Center Tenaya
Las Vegas, Nevada
NYU Langone Hospital - Long Island
Mineola, New York
Cleveland Clinic
Cleveland, Ohio
Victorium Clinical Research - Houston
Houston, Texas
Endocrine Ips, Pllc
Houston, Texas
Tranquility Research
Webster, Texas
Centricity Research Brampton Endocrinology
Brampton, Ontario, Canada
Circulate Cardiac & Vascular Centre
Burlington, Ontario, Canada
North York Diagnostic and Cardiac Centre
North York, Ontario, Canada
Stouffville Medical Research Institute Inc.
Stouffville, Ontario, Canada
Dr. Anil K. Gupta Medicine Professional Corporation
Toronto, Ontario, Canada
Fadia El Boreky Medicine
Waterloo, Ontario, Canada
Viacar Recherche Clinique
Greenfield Park, Quebec, Canada
Diex Recherche Joliette
Joliette, Quebec, Canada
9109-0126 Quebec Inc.
Montreal, Quebec, Canada
Azienda Socio Sanitaria Territoriale Papa Giovanni XXIII
Bergamo, Italy
Ospedale San Raffaele
Milan, Italy
Centro Cardiologico Monzino
Milan, Milano, Italy
Azienda Ospedaliera Universitaria Pisana
Pisa, Tuscany, Italy
Clínica nuevas Tecnologías en Diabetes y Endocrinología (NTDE)
Seville, Spain
Hospital Clinico de Valencia
Valencia, Valenciana, Comunitat, Spain
Hospital Universitario Doctor Peset
Valencia, Valenciana, Comunitat, Spain
City Hospital, Nottingham University Hospitals NHS Trust
Nottingham, United Kingdom
Addenbrooke's Hospital
Cambridge, Cambridgeshire, United Kingdom
FutureMeds Teesside - Middlefield Centre
Stockton-on-Tees, Durham County, United Kingdom
Royal London Hospital
London, England, United Kingdom
Futuremeds-Newcastle
Newcastle, England, United Kingdom
Showing 40 of 42 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.